There is a proposal to offer coverage for a breast cancer screening program to women aged 20-40 in your Health Maintenance Organization (HMO). There are doubts about the effectiveness of such a screening program. We present here four statements derived from four randomized controlled trials published in the literature pertaining to breast cancer screening. O n the basis of each statement, you should indcate how likely you are to agree to the implementation of a breast cancer screening program. Assume that the costs of each program are the same. Each result was deemed to be statistically significant. During a 7-year follow-up:
Program A reduced the death rate from breast cancer by 33% Program B produced an absolute reductionin deaths from breast If you choose program A, you are thnking like the majority of physicians,' who on first reflection identified hghest number with the greatest benefit. After gving some thought to a problem (see below), we of course all understand that each program above offers identical benefits. We simply failed to appreciate the difference between relative and absolute measures in expressing treatment benefits. We are often asked (and mandated by numerous agencies and regulatory bodes) to discuss the benefits and harms of treatment interventions with our patients. But, what exactly do we mean by 'treatment benefits and harms'? In t h s tutorial we will try to shed some light on t h s issue. 
MEASURES OF BENEFITS AND HARMS ARE

COMPARATIVE MEASURES BETWEEN ALTERNATIVE TREATMENT OPTIONS
THREE WAYS OF COMPARISON: DIFFERENCE, RELATIVE RISK (PROPORTIONS) AND RATIOS
Since the 'bread and butter' for data on treatment benefit comes from the analysis of survival data, we will attempt to derive clinical useful measures of treatment benefit from survival curves. Figure 1 shows data that can be derived from survival c~r v e s .~'~ Let us assume that two curves represent survival data after treatment of a gven cancer with standard (control) (C) therapy and new chemotherapy (experimental therapy) (E). We can compare survival probabilities for these two treatments at a point of interest (say, 5 years) in terms (1) direct or absolute difference as
Let us see now how these simple relationshps can be converted into palpable benefits for our patients. We said above that the second step is to determine if we are increasing good events or preventing bad events. Let us say we would like to deduce from Fig. 1 the efficacy of experimental treatment in terms of survival (good event) at 5 years. We see that at 5 years, approximately 33% of patients on treatment E are estimated to be ahve vs. 25% those on treatment C. T h s can be converted into: (1) absolute benefit increase (ABI) of 8% (33 -25 = 8), (2) relative benefit increase (RBI) of 32% [(33 -25)/25 = 32%], or (3) relative benefit of 1.32 (33/25). Note that benefit in terms of direct ratio can also be expressed as commonly used, but not that popular odds ratio (OR), whch can be defined as p / (
62, meaning that odds of survival for experimental treatment is 2.62 times hgher than the odds of survival for control treatment.
Often in the literature, benefits are presented in terms of preventing bad events. In our case, the bad event is mortality, whch is equal to 100-survival (?/o). Repeating the exercise presented above for our example, we can define the following measures of benefit: We should note here that in t h s tutorial we are not addressing hazard ratio, whch is one of the most appropriate summary statistics when it comes to comparison of time-to-event data. A reader is referred to the article on survival analysis written by one of us in the last issue of EBO.' N N T AND N N H One very popular measure to express benefits in clinical terms is to calculate NNT, which denotes the number of patients who need to be treated with experimental therapy in order to have one additional favorable outcome in comparison with the control T h s is equal to N N T = 1/ABI or N N T = l/ARR, whch in our case is 12.5 (and by convention t h s was rounded to the hghest integer number, 13). T h s means we need to treat 13 patients with experimental treatment for 5 years to prevent one death (or save one life).
It should be obvious by now that all of these measures are equivalent. However, relative measures tend to be more impressive and are, therefore, more often used. Unfortunately, our decisions can be easily influenced by the format of presentation of the measures of benefits (and harms) as shown in the introductory example.',*
It is important to note that N N T dramatically changes with the absolute difference, whle RRR does not. above example survival difference was 3.3 vs. 2.5%, RBI sull remains 32%, but N N T dramatically increases to 125. In calculations like these it is also assumed that RRR or RBI are constant over time, whch may or may not be true.
Measures of harm relate to increase in the number of bad events and can be analogously derived. They are commonly expressed as relative risk increase (RRI), absolute risk increase (ARI) and the number of patients (NNW who, if they receive experimental treatment, would lead to one additional person being harmed compared with patients who receive the control treatment;
(NNH = 1 1~~9 .~ DETERMINING LIFE EXPECTANCY WMe all measures of benefits and harms defined above are useful, they are not easily grasped by patients. Patients often want to know how many years they have to live, i.e. they want us to determine their life expectancy. T h s information is also available from survival curves. Life expectancy is equal to the area under survival curve (AUC) of a gven treatment.? The gain in LE(ALE) between two treatments is, thus, equal to the dfference between AUC for experimental and control treatment? (Fig. 1) . However, determination of AUC is not that easy to do. Fortunately, there exists a simple method that can help us determine LE relatively accurately for most situations in oncology. T h s method termed declining exponential approximation of life expectancy (DEALE) is accurate when the disease-specific mortality rate exceeds 10% per year.','' In these cases, the error in calculation of LE is less than 1 year regardless of the age of the patient. DEALE is based on the assumption that in some diseases, such as cancer, the mortahty rate (m) is constant and survival thus can be described by a declining exponential function. According to the DEALE method the patient-specific LE is equal to where mp, refers to patient-specific mortahty. In turn, mp, is equal to sum of age-sex-race-related mortality (mJ and disease-specific mortahty (md:
where m,, represent the mortality rates for the specific disease that the patient has. We assume here, for simplicity, that a patient has one disease. In the case that our patient has more than one dmase, we would simply add together the disease-specific mortalities of all diseases. According to the DEALE an average annual mortality rate, ma,, is
where In is the natural logarithm, t the time at whch the fractional survival is measured and S the proportion of patients sull alive at time t. Note that ma, is what is available from survival analysis in the literature.
If our patient is similar to a study population for whch we have a survival curve, then mp, = map. In our example (Fig. l) , the 5-year survival was 0.33 and 0.25 for experimental and control treatment, respectively. T h s is equal to ma, of 0.222 per year for experimental and 0.277 per year for control treatment, whch converts into LE of 4.5 and 3.6 years, respectively. Gain in LE with experimental treatment is, thus, equal to ALE = 4.5 -3.6 = 0.9 years.* We should also note that the DEALE method is relevant only for those patients with a dsease for whch there is no cure. If the survival curve has a plateau, the area under the curve is infinite. In the case of cure, using an estimate of the probability of cure would be more appropriate than calculation of life expectancy.
It is important to understand that the gain in LE is an average value. T h s means that a gain in LE means that either all of the patients treated with a gven therapy obtain a small increase in life span, or some patients enjoy a large increase in LE.? Thus, the gain in LE should be interpreted probabilistically and is related to a shft in survival curve to the right (see Fig. 1 ). T h s shft implies an immediate increase in the probability of survival in comparison with control T h s is important to understand because it is commonly misconceived that a gain in LE means 'adding time (years) to life'. In our example above, it means that 0.9 years (329 days) of gain in LE with experimental treatment over control is not simply added to control LE, but is rather evenly distributed resulting in an average gain of 11 months of LE (the actual increase for a gven patient may be large, close to zero, or even negative).?
Second, equally effective treatments in terms of absolute or relative measures of benefit will convert into different gains in LE dependmg on the slope of the survival curve (i.e. baseline risk of death). If the slope of the survival curve is steeper a gain in LE will be smaller, and vice versa.? Finally, Figure 1 shows another important piece of information often used in oncology. It refers to median survival times or the time at which half of the cohort patients have died. Note that ma, can also be calculated from the median survival time as 0.693/t and used with the DEALE method.',' ' We hope that we have shown how the richness and complexity of survival curves can be translated into useful measures that help us summarize the magnitude of treatment effects. Several seemingly different measures are obtained from the same comparative data. In future tutorials we hope to show how data on benefits and harms can be used in decision-making at the bedside in indvidual patients.
